Posters

      Reduced exposure to harmful and potentially harmful constituents after 90 days of use of tobacco heating system 2.2 menthol in the U.S.: A comparison with continued cigarette use or smoking abstinence

      Haziza, C.; de La Bourdonnaye, G.; Picavet, P.; Baker, G.; Skiada, D.; Merlet, S.; Franzon, M.; Farmer, F.; Lewis, W.; Lüdicke, F.

      Conference date
      Nov 10, 2015
      Conference name
      American College of Toxicology (ACT) 2015
      Link to more information
      Link to more information
      Topic
      Summary

      The Tobacco Heating System 2.2 menthol (mTHS) was developed to reduce or eliminate the formation of harmful and potentially harmful smoke constituents (HPHCs) in the aerosol through heating and not burning tobacco, while preserving as much as possible taste, sensory experience, nicotine delivery profile and ritual characteristics of menthol cigarettes (mCC). The study reported is part of a global clinical program for THS and was designed to demonstrate sustained exposure reduction to selected HPHCs in smokers pre-dominantly using mTHS and to provide first insight on changes in clinical risk endpoints (CRE) when switching from mCC to mTHS use for 5 days in confinement followed by an ambulatory period of 85 days, compared to subjects continuing to smoke mCC and those who abstained from smoking.Biomarkers of exposure (BoExp) to 16 HPHCs were assessed to provide an assessment of human uptake of a variety of representative toxicants contained in combustible tobacco products. Selected CREs associated with cardiovascular, respiratory disease and genotoxicity as well as subjective effects to investigate the acceptance of mTHS compared to mCC were also assessed in this study.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.